(Q34688577)

3 August 2017

1 reference

title

Culprit and victim -- DNA topoisomerase II. (English)

1 reference

3 August 2017

Frank Gieseler

4

1 reference

ORCID Public Data File 2021

author name string

Udo Kellner

1

1 reference

3 August 2017

Maxwell Sehested

2

1 reference

3 August 2017

Peter B Jensen

3

1 reference

3 August 2017

Pierre Rudolph

5

1 reference

3 August 2017

1 April 2002

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

3

1 reference

3 August 2017

235-243

1 reference

3 August 2017

4

1 reference

Structure and mechanism of DNA topoisomerase II

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

New break for archaeal enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

The clinical pharmacology of etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Investigating the biological functions of DNA topoisomerases in eukaryotic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

1 reference

7 January 2021

Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Enhanced expression of Ki-67, topoisomerase IIalpha, PCNA, p53 and p21WAF1/Cip1 reflecting proliferation and repair activity in UV-irradiated melanocytic nevi

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Physiological regulation of eukaryotic topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Cell-cycle regulation of the DNA topoisomerase IIalpha promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms alpha and beta

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

DNA topoisomerase IIbeta and neural development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Detection of human topoisomerase II alpha in cell lines and tissues: characterization of five novel monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

The response of eukaryotic topoisomerases to DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Functional interaction between human topoisomerase IIalpha and retinoblastoma protein

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

14-3-3 proteins: key regulators of cell division, signalling and apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Modulation of human DNA topoisomerase IIalpha function by interaction with 14-3-3epsilon

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Chromosome recombination and defective genome segregation induced in Chinese hamster cells by the topoisomerase II inhibitor VM-26

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Crystal structure of NaeI--an evolutionary bridge between DNA endonuclease and topoisomerase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Chromosome organization and genic expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Mutagenic properties of topoisomerase-targeted drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Amplification of the topoisomerase II alpha gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II alpha and beta loci in normal tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

KiS1--a novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Clinical applications of anticancer drugs targeted to topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Cell death induced by topoisomerase-targeted drugs: more questions than answers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Caspase activation in MCF7 cells responding to etoposide treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

DNA topoisomerase I and II as targets for rational design of new anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Changes in nuclear protein kinase C-delta holoenzyme, its catalytic fragments, and its activity in polyomavirus-transformed pyF111 rat fibroblasts while proliferating and following exposure to apoptogenic topoisomerase-II inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Anthracycline drug targeting: cytoplasmic versus nuclear--a fork in the road

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

XK469, a selective topoisomerase IIbeta poison

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

P-glycoprotein as a drug target in the treatment of multidrug resistant cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

DNA topoisomerase II mutations and resistance to anti-tumor drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Cleavage of the Bloom's syndrome gene product during apoptosis by caspase-3 results in an impaired interaction with topoisomerase IIIalpha

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900715-5

7 January 2021

10.1016/S1470-2045(02)00715-5

Identifiers

DOI

1 reference

3 August 2017

1 reference